Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2014
10/02/2014WO2014160121A1 Humanized antibodies specific for staphylococcal enterotoxin b
10/02/2014WO2014160098A2 Bordetella specific human recombinant antibodies and uses thereof
10/02/2014WO2014160092A1 Adeno-associated virus vectors and methods of use thereof
10/02/2014WO2014160088A2 Treating hepatitis b virus infections
10/02/2014WO2014159940A1 Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
10/02/2014WO2014159923A1 Enhancement of vaccines
10/02/2014WO2014159915A1 Her3 specific monoclonal antibodies for diagnostic and therapeutic use
10/02/2014WO2014159911A1 Compositions comprising anti-cd38 antibodies and carfilzomib
10/02/2014WO2014159835A1 Anti-b7-h4 antibodies and immunoconjugates
10/02/2014WO2014159822A2 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
10/02/2014WO2014159764A1 Chrdl-1 antigen binding proteins and methods of treatment
10/02/2014WO2014159725A1 Proteins specific for baff and b7rp1 and uses thereof
10/02/2014WO2014159609A1 Peanut formulations and uses thereof
10/02/2014WO2014159607A1 Manufacture of peanut formulations for oral desensitization
10/02/2014WO2014159592A2 Modified hyaluronan and uses thereof in cancer treatment
10/02/2014WO2014159580A1 Met-binding agents and uses thereof
10/02/2014WO2014159550A1 Diffocins and methods of use thereof
10/02/2014WO2014159430A1 Anti-rankl antibodies and methods of use
10/02/2014WO2014159052A1 Vaccination of companion animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission
10/02/2014WO2014159010A1 Human antibodies to grem 1
10/02/2014WO2014158821A1 Antigen binding constructs to cd70
10/02/2014WO2014158811A1 Newcastle disease viruses and uses thereof
10/02/2014WO2014158542A1 Biomarkers for detecting the presence of bacteria
10/02/2014WO2014158272A1 Hcv antigen-antibody combination assay and methods and compositions for use therein
10/02/2014WO2014158123A1 Gene optimized hantaan virus m segment dna vaccine for hemorrhagic fever with renal syndrome
10/02/2014WO2014158001A1 Composition comprising at least two influenza a virus-neutralizing-binding molecules
10/02/2014WO2014157952A1 Novel syndecan-2 fragment and use thereof
10/02/2014WO2014157918A1 Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
10/02/2014WO2014157704A1 Conjugate vaccine using trimming function of erap1
10/02/2014WO2014157692A1 Wt1-antigen peptide conjugate vaccine
10/02/2014WO2014157595A1 Novel polypeptides and utilization thereof
10/02/2014WO2014157229A1 Tace peptide epitope, antihuman tace protein antibody and hybridoma producing antibody
10/02/2014WO2014155297A2 Systems and methods for viral inactivation of vaccine compositions by treatment with carbohydrates and radiation
10/02/2014WO2014155294A1 Vaccines for the prevention of infections with bordetella
10/02/2014WO2014155268A2 Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
10/02/2014WO2014155145A1 Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
10/02/2014WO2014155135A1 Methods for the treatment of autoimmune diseases
10/02/2014WO2014154930A1 Anti-factor b antibody, pharmaceutical composition that can be used for the treatment of diseases of the complement system, and uses thereof
10/02/2014WO2014154905A1 A cancer vaccine for dogs
10/02/2014WO2014154904A1 A cancer vaccine for cats
10/02/2014WO2014154847A1 Vaccine against rhipicephalus ticks
10/02/2014WO2014154655A1 Stabilised fmdv capsids
10/02/2014WO2014154134A1 Polypeptide having inhibitory effect against infection by novel coronavirus hcov-emc 2012 and application of the polypeptide
10/02/2014WO2014153674A1 Influenza virus-like particle production in plants
10/02/2014WO2014153636A1 Method for improving the efficacy of a survivin vaccine in the treatment of cancer
10/02/2014US20140296498 Tiacumicin Production
10/02/2014US20140296493 METHOD OF TREATING DEPRESSION USING A TNFa ANTIBODY
10/02/2014US20140296179 Nutritional composition comprising immunoglobulins and oligosaccharides
10/02/2014US20140296101 Secreted proteins and uses thereof
10/02/2014US20140295409 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
10/02/2014US20140294982 Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions
10/02/2014US20140294935 Vaccine composition
10/02/2014US20140294919 Vaccines
10/02/2014US20140294898 Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
10/02/2014US20140294896 Cancer antigen
10/02/2014US20140294895 Expression of Protective Antigens in Transgenic Chloroplasts and the Production of Improved Vaccines
10/02/2014US20140294894 Transcutaneous delivery of therapeutic agents
10/02/2014US20140294892 Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
10/02/2014US20140294891 Microorganisms for therapy
10/02/2014US20140294889 Use of the pacap as a molecular adjuvant for vaccines
10/02/2014US20140294887 Adjuvanting meningococcal factor h binding protein
10/02/2014US20140294886 Isolated protein and compositions comprising the protein
10/02/2014US20140294884 Meningococcus adhesins nada, app and orf 40
10/02/2014US20140294883 Vaccine
10/02/2014US20140294882 Compositions and methods for detecting, treating, and protecting against fusobacterium infection
10/02/2014US20140294880 Mutated lentiviral env proteins and their use as drugs
10/02/2014US20140294876 Amyloid Beta 1-6 Antigen Arrays
10/02/2014US20140294875 Leishmania Vaccine Using Sand Fly Salivary Immunogen
10/02/2014US20140294871 Amino acid sequences for controlling pathogens
10/02/2014US20140294869 Immune tolerance inducer
10/02/2014US20140294862 Methods of modulating the negative chemotaxis of immune cells
10/02/2014US20140294859 Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
10/02/2014US20140294857 Methods of obtaining a specific binding member that binds eotaxin
10/02/2014US20140294855 Small molecule screening for mouse satellite cell proliferation
10/02/2014US20140294849 Compositions and uses
10/02/2014US20140294842 Assays, Methods and Means
10/02/2014US20140294830 Method of combination therapy using an egfr antagonist and anti-c-met antibody
10/02/2014US20140294829 Anti-ngf antibodies for the treatment of various disorders
10/02/2014US20140294827 Fully Human Antibodies that Bind to VEGFR2
10/02/2014US20140294820 Fibroblast growth factor receptor inhibition for the treatment of disease
10/02/2014US20140294816 Combination therapy for the treatment of ocular neovascular disorders
10/02/2014US20140294811 Method for predicting risk of hypertension associated with anti-angiogenesis therapy
10/02/2014US20140294807 Combination therapy with type i and type ii anti-cd20 antibodies
10/02/2014US20140294803 Methods for treating headache
10/02/2014US20140294768 Responsiveness to angiogenesis inhibitors
10/02/2014US20140294765 Lsr antibodies, and uses thereof for treatment of cancer
10/02/2014US20140294757 Stabilisation of polypeptides
10/02/2014US20140294731 Phosphospecific antibodies recognising tau
10/02/2014US20140294723 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart
10/02/2014DE102013103109A1 Verfahren und Kit für den Nachweis von Lebensmittel-Allergenen A method and kit for the detection of food allergens
10/01/2014EP2784088A2 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv)
10/01/2014EP2784084A1 IL-17 A/F heterologous polypeptides and therapeutics uses thereof
10/01/2014EP2784082A1 Disease site-delivering pharmaceutical compositions comprising paclitaxel.
10/01/2014EP2783701A2 Extended treatment of multiple sclerosis
10/01/2014EP2783700A1 Cancer stem cell-targeted cancer therapy
10/01/2014EP2783699A1 Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
10/01/2014EP2783694A2 Peptide sequences and compositions from Anopheles gambiase
10/01/2014EP2783014A1 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
10/01/2014EP2782930A1 Methods of regulating angiogenesis and compositions capable of same
10/01/2014EP2782927A1 Hla-dr7 hy epitope and method for treating leukemia
1 ... 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 ... 1823